Expression of COX-2 proteins in gastric mucosal lesions

Table 1 COX-2 expression in gastric cancer and paracancerous tissues

	Number	COX-2 expression intensityb				Positive
		-	+	++	+++	ratedn (%)
Gastric cancer	30	10	4	8	8	20 (66.7)
Paracancerous tissue	30	22	6	2	0	8 (26.7)

^bP < 0.001 gastric cancer vs paracancerous tissue;

^dP < 0.01 gas-tric cancer vs paracancerous tissue.

Table 2 COX-2 expression in gastric mucosa with H pylori infection, n (%)

	CG (n = 30)		IM (n = 19)		DYS (n = 11)		GC (n = 30)
	Hp+	Hp -	Hp+	Hp -	Hp +	Hp -	Hp +	Hp -
n	25	5	9	11	5	6	11	19
COX-2	2 (8.0%)	1 (0%)	5 (50.6%)a	2 (18.1%)	3 (60.0%)a	2 (33.3%)	8 (72.7%)	12 (63.5%)

^aP < 0.05, IM or DYS (H pylori positive) vs IM or DYS (H pylori negative).

Table 3 COX-2 expression in gastric cancer tissues

Groups	Number	COX-2 n (%)
Type
Intestinal type	24	16 (66.7)
Gastric type	6	4 (66.7)
Stage
Early stage	5	1 (20.0)
Developing	25	19 (76.0)a
Differentiation (Intestinal type)
High and moderate	14	8 (57.1)
Low and no differentiation	10	8 (80.0)
Lymph node metastasis
Without metastasis	6	1 (16.7)
With metastasis	24	19 (79.2)a

^aP < 0.05, developing stage vs early stage; metastasis vs no metastasis.